Symptom management in patients with multiple sclerosis
暂无分享,去创建一个
[1] R. Newell,et al. Treatment of fatigue in multiple sclerosis: a systematic review of the literature. , 2008, International journal of nursing practice.
[2] T. Ziemssen,et al. Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis , 2008, Health and quality of life outcomes.
[3] K. Trinkaus,et al. Comparative assessment of Yale Single Q uestion and Beck Depression Inventory Scale in screening for depression in multiple sclerosis , 2003, Multiple sclerosis.
[4] Rohit Bakshi,et al. Quality of life in patients with multiple sclerosis The impact of fatigue and depression , 2002, Journal of the Neurological Sciences.
[5] P. Rieckmann,et al. Symptomatic Treatment of Multiple Sclerosis , 2006, European Neurology.
[6] D. Ehde,et al. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. , 2002, The American journal of psychiatry.
[7] E. McDonald,et al. Living with multiple sclerosis: longitudinal changes in employment and the importance of symptom management , 2010, Journal of Neurology.
[8] D. Wade,et al. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis , 2010, Multiple sclerosis.
[9] D. Mohr,et al. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. , 1997, Archives of neurology.
[10] B. Saletu,et al. Depression and quality of life in multiple sclerosis , 2001, Acta neurologica Scandinavica.
[11] M. Weiner,et al. Postexercise phosphocreatine resynthesis is slowed in multiple sclerosis , 1994, Muscle & nerve.
[12] H. Reichmann,et al. Neurological disability, psychological distress, and health-related quality of life in MS patients within the first three years after diagnosis , 2009, Multiple sclerosis.
[13] P. Rieckmann,et al. Multiple sclerosis registry in Germany: results of the extension phase 2005/2006. , 2008, Deutsches Arzteblatt international.
[14] D. Mohr,et al. Treatment of depression for patients with multiple sclerosis in neurology clinics , 2006, Multiple sclerosis.
[15] Tjalf Ziemssen,et al. Multiple sclerosis beyond EDSS: depression and fatigue , 2009, Journal of the Neurological Sciences.
[16] T. Talvik,et al. One question as a screening instrument for depression in people with multiple sclerosis , 2007, Clinical rehabilitation.
[17] H. Rossman,et al. A multimodal approach to managing the symptoms of multiple sclerosis , 2004, Neurology.
[18] M. Amato,et al. Quality of life in multiple sclerosis: the impact of depression, fatigue and disability , 2001, Multiple sclerosis.
[19] C. Dickinson,et al. Chronic fatigue syndrome—aetiological aspects , 1997, European journal of clinical investigation.
[20] J. Oger,et al. Depression and multiple sclerosis , 1996, Neurology.
[21] L. Krupp,et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial , 2009, The Lancet.
[22] J. Beaumont. The MS symptom and impact diary (MSSID): psychometric evaluation of a new instrument to measure the day to day impact of multiple sclerosis , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[23] T. Ziemssen,et al. Review: Brain—immune communication psychoneuroimmunology of multiple sclerosis , 2008, Multiple sclerosis.
[24] W. Ammann,et al. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue , 1997, Neurology.
[25] P. Peterson,et al. Immunologically mediated fatigue: a murine model. , 1992, Clinical immunology and immunopathology.
[26] A Achiron,et al. Fatigue in multiple sclerosis compared with chronic fatigue syndrome , 1996, Neurology.
[27] S. Gold,et al. Endocrine and Cytokine Responses to Acute Psychological Stress in Multiple Sclerosis , 2002, Brain, Behavior, and Immunity.
[28] U. Dalgas. Rehabilitation and multiple sclerosis: hot topics in the preservation of physical functioning , 2011, Journal of the Neurological Sciences.
[29] S. Patten,et al. The effect of immunomodulatory treatment on multiple sclerosis fatigue , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[30] S. Patten,et al. Major depression in multiple sclerosis , 2003, Neurology.
[31] B. Cohen. Identification, causation, alleviation, and prevention of complications (ICAP) , 2008, Neurology.
[32] P. Dorman,et al. Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis , 1997, BMJ.
[33] A F Long,et al. The MS Symptom and Impact Diary (MSSID): psychometric evaluation of a new instrument to measure the day to day impact of multiple sclerosis , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[34] R. Zivadinov,et al. Sexual dysfunction in multiple sderosis: a case-control study. 1. Frequency and comparison of groups , 1999, Multiple sclerosis.
[35] R. Nixon,et al. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[36] R. Zivadinov,et al. Sexual dysfunction in multiple sclerosis: a 2-year follow-up study , 2001, Journal of the Neurological Sciences.
[37] A Mauro,et al. Depression is the main determinant of quality of life in multiple sclerosis: A classification-regression (CART) study , 2006, Disability and rehabilitation.